Physician profile
Igor Levy Reis
NPI 1629077508
$20,991.58
in general payments reported to CMS, 2019-2025
63 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,781 · 2020: $2,554 · 2021: $2,764 · 2022: $3,192 · 2023: $3,126 · 2024: $4,479 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,700.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,482.45 | 2020-2025 | Briviact, Zilbrysq, Nayzilam |
| Abbvie INC. | $2,139.27 | 2019-2025 | |
| Allergan, INC. | $1,454.19 | 2019-2022 | |
| Ge Healthcare | $1,176.94 | 2019-2025 | |
| Eisai INC. | $867.38 | 2021-2025 | |
| Argenx US, INC. | $847.29 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $760.84 | 2022-2025 | Vyepti, Rexulti |
| Amgen INC. | $745.94 | 2019-2022 | |
| Octapharma USA, INC. | $714.21 | 2022-2024 | Octagam Immune Globulin (Human), Panzyga |
| Neurocrine Biosciences, INC. | $681.22 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $680.99 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $606.27 | 2019-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $507.40 | 2022-2024 | Onpattro |
| Tanabe Pharma America, INC. | $493.58 | 2019-2025 | Radicava |
| Takeda Pharmaceuticals U.S.A., INC. | $481.75 | 2021-2025 | Hyqvia, Gammagard |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Reis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.